Go Pro
→ Trump Takes Emergency Action - Plus Elon Musk's New Venture (From Altimetry) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
argenex SE stock logo
ARGX
argenex
$987.84
+16.0%		$881.73
$650.01
▼
$1,002.16
$61.80B0.46349,277 shs680,419 shs
Insmed, Inc. stock logo
INSM
Insmed
$128.32
+3.7%		$107.88
$90.39
▼
$212.75
$28.02B0.813.09 million shs1.90 million shs
Natera, Inc. stock logo
NTRA
Natera
$314.18
+1.4%		$263.76
$156.71
▼
$326.03
$45.29B1.511.36 million shs1.07 million shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$805.93
+0.3%		$675.79
$541.00
▼
$821.11
$82.98B0.21853,508 shs541,264 shs
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
argenex SE stock logo
ARGX
argenex
0.00%-1.59%-1.08%+9.67%+30.20%
Insmed, Inc. stock logo
INSM
Insmed
0.00%-5.61%+14.24%+15.48%-3.18%
Natera, Inc. stock logo
NTRA
Natera
0.00%-3.78%+14.20%+60.97%+90.12%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.00%+2.44%+18.74%+27.60%+38.43%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
argenex SE stock logo
ARGX
argenex
$987.84
+16.0%		$881.73
$650.01
▼
$1,002.16
$61.80B0.46349,277 shs680,419 shs
Insmed, Inc. stock logo
INSM
Insmed
$128.32
+3.7%		$107.88
$90.39
▼
$212.75
$28.02B0.813.09 million shs1.90 million shs
Natera, Inc. stock logo
NTRA
Natera
$314.18
+1.4%		$263.76
$156.71
▼
$326.03
$45.29B1.511.36 million shs1.07 million shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$805.93
+0.3%		$675.79
$541.00
▼
$821.11
$82.98B0.21853,508 shs541,264 shs
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
argenex SE stock logo
ARGX
argenex
0.00%-1.59%-1.08%+9.67%+30.20%
Insmed, Inc. stock logo
INSM
Insmed
0.00%-5.61%+14.24%+15.48%-3.18%
Natera, Inc. stock logo
NTRA
Natera
0.00%-3.78%+14.20%+60.97%+90.12%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.00%+2.44%+18.74%+27.60%+38.43%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
argenex SE stock logo
ARGX
argenex
2.92
Moderate Buy$1,072.728.64% Upside
Insmed, Inc. stock logo
INSM
Insmed
3.00
Buy$205.5262.18% Upside
Natera, Inc. stock logo
NTRA
Natera
2.82
Moderate Buy$319.380.65% Upside
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
2.62
Moderate Buy$801.70-1.07% Downside

Current Analyst Ratings Breakdown

Latest INSM, REGN, ARGX, and NTRA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/17/2026
argenex SE stock logo
ARGX
argenex
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$1,075.00 ➝ $1,215.00
8/17/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetMarket Perform$641.00 ➝ $824.00
8/13/2026
Natera, Inc. stock logo
NTRA
Natera
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$315.00 ➝ $365.00
8/12/2026
Natera, Inc. stock logo
NTRA
Natera
Stephens logo
Stephens
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$305.00 ➝ $350.00
8/12/2026
Natera, Inc. stock logo
NTRA
Natera
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$290.00 ➝ $360.00
8/12/2026
Natera, Inc. stock logo
NTRA
Natera
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
8/12/2026
Natera, Inc. stock logo
NTRA
Natera
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$249.00 ➝ $363.50
8/10/2026
Insmed, Inc. stock logo
INSM
Insmed
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$185.00 ➝ $195.00
8/10/2026
Natera, Inc. stock logo
NTRA
Natera
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$355.00
8/10/2026
Insmed, Inc. stock logo
INSM
Insmed
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/10/2026
Insmed, Inc. stock logo
INSM
Insmed
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$179.00 ➝ $175.00
(Data available from 8/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
argenex SE stock logo
ARGX
argenex
$4.25B14.54$24.75 per share39.90$118.34 per share8.34
Insmed, Inc. stock logo
INSM
Insmed
$606.42M45.63N/AN/A$3.46 per share36.62
Natera, Inc. stock logo
NTRA
Natera
$2.31B19.83N/AN/A$12.38 per share25.63
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$14.34B5.82$42.34 per share19.14$295.66 per share2.74
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
argenex SE stock logo
ARGX
argenex
$1.29B$26.0437.9127.161.0532.19%43.59%36.66%N/A
Insmed, Inc. stock logo
INSM
Insmed
-$1.28B-$4.11N/A48.55N/A-76.94%-123.94%-44.30%10/29/2026 (Estimated)
Natera, Inc. stock logo
NTRA
Natera
-$208.16M-$1.36N/A31,729.90N/A-7.11%-11.38%-7.87%11/5/2026 (Estimated)
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$4.50B$40.4620.0516.041.3727.86%13.47%10.34%10/28/2026 (Estimated)

Latest INSM, REGN, ARGX, and NTRA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Insmed, Inc. stock logo
INSM
Insmed
-$0.6724-$0.06+$0.6124-$0.06$395.50 million$425.49 million
8/6/2026Q2 2026
Natera, Inc. stock logo
NTRA
Natera
-$0.4939-$0.47+$0.0239-$0.47$661.24 million$752.75 million
7/30/2026Q2 2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$10.16$14.29+$4.13$12.23$3.82 billion$4.29 billion
7/21/2026Q2 2026
argenex SE stock logo
ARGX
argenex
$5.86$7.32+$1.46$7.32$1.45 billion$1.54 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
argenex SE stock logo
ARGX
argenex
N/AN/AN/AN/AN/A
Insmed, Inc. stock logo
INSM
Insmed
N/AN/AN/AN/AN/A
Natera, Inc. stock logo
NTRA
Natera
N/AN/AN/AN/AN/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$3.760.46%N/A9.29%N/A

Latest INSM, REGN, ARGX, and NTRA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/30/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
quarterly$0.940.51%8/18/20268/18/20268/31/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
argenex SE stock logo
ARGX
argenex
N/A
5.12
4.89
Insmed, Inc. stock logo
INSM
Insmed
0.74
3.72
3.40
Natera, Inc. stock logo
NTRA
Natera
N/A
3.00
2.85
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.06
3.34
2.78

Institutional Ownership

CompanyInstitutional Ownership
argenex SE stock logo
ARGX
argenex
60.32%
Insmed, Inc. stock logo
INSM
Insmed
N/A
Natera, Inc. stock logo
NTRA
Natera
99.90%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
83.31%

Insider Ownership

CompanyInsider Ownership
argenex SE stock logo
ARGX
argenex
2.43%
Insmed, Inc. stock logo
INSM
Insmed
2.10%
Natera, Inc. stock logo
NTRA
Natera
5.05%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
6.97%
CompanyEmployeesShares OutstandingFree FloatOptionable
argenex SE stock logo
ARGX
argenex
1,86362.56 million61.04 millionOptionable
Insmed, Inc. stock logo
INSM
Insmed
1,664218.38 million213.80 millionOptionable
Natera, Inc. stock logo
NTRA
Natera
6,140144.14 million136.87 millionOptionable
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
15,410102.96 million95.78 millionOptionable

Recent News About These Companies

Can Regeneron Pharmaceuticals (NASDAQ:REGN) Extend Its Run?
 |  kalkinemedia.comK
EyePoint Stock Craters 69% After Drug Trial Failure. It May Be an Overreaction.
 |  finance.yahoo.comhttps://finance.yahoo.com/m/5f9c249b-3d97-33a6-b402-fb255af632dd/eyepoint-stock-craters-69%25.html
REGN UPCOMING DEADLINE: Levi & Korsinsky Alerts Regeneron Pharmaceuticals, Inc. Stockholders of Securities Class Action - Contact the Firm
 |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/17/3346363/3080/en/regn-upcoming-deadline-levi-korsinsky-alerts-regeneron-pharmaceuticals-inc-stockholders-of-securities-class-action-contact-the-firm.html
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
August 17 at 10:16 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/17/3346215/0/en/regn-investors-have-opportunity-to-lead-regeneron-pharmaceuticals-inc-securities-fraud-lawsuit-with-the-schall-law-firm.html
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $824.00 at Leerink Partners
August 17 at 8:41 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/regeneron-pharmaceuticals-nasdaqregn-price-target-raised-to-82400-at-leerink-partners-2026-08-17/
Plato Investment Management Ltd Makes New $2.47 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN
August 17 at 6:31 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-plato-investment-management-ltd-makes-new-247-million-investment-in-regeneron-pharmaceuticals-inc-regn-2026-08-17/
Oppenheimer Asset Management Inc. Takes $1.50 Million Position in Regeneron Pharmaceuticals, Inc. $REGN
August 17 at 5:19 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-oppenheimer-asset-management-inc-takes-150-million-position-in-regeneron-pharmaceuticals-inc-regn-2026-08-17/
Focus Partners Advisor Solutions LLC Invests $1.35 Million in Regeneron Pharmaceuticals, Inc. $REGN
August 17 at 3:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-focus-partners-advisor-solutions-llc-invests-135-million-in-regeneron-pharmaceuticals-inc-regn-2026-08-17/
AMG National Trust Bank Makes New $1.22 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN
August 17 at 3:12 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-amg-national-trust-bank-makes-new-122-million-investment-in-regeneron-pharmaceuticals-inc-regn-2026-08-17/
Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
August 16 at 12:00 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/16/3345782/9788/en/bronstein-gewirtz-grossman-llc-urges-regeneron-pharmaceuticals-inc-investors-to-act-class-action-filed-alleging-investor-harm.html
USA Financial Formulas Acquires New Position in Regeneron Pharmaceuticals, Inc. $REGN
August 16 at 6:07 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-usa-financial-formulas-acquires-new-position-in-regeneron-pharmaceuticals-inc-regn-2026-08-16/
REGN INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026
August 15 at 9:31 PM  |  newsfilecorp.comN
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – REGN
August 15 at 10:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/15/3345720/1087/en/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-regeneron-pharmaceuticals-inc-of-class-action-lawsuit-and-upcoming-deadlines-regn.html
7,506 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Summit Global Investments
August 15 at 6:55 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-7506-shares-in-regeneron-pharmaceuticals-inc-regn-acquired-by-summit-global-investments-2026-08-15/
Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded to "Strong-Buy" at Wall Street Zen
August 15 at 1:54 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30961527
Wall Street Zen Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Strong-Buy
August 15 at 1:53 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/wall-street-zen-upgrades-regeneron-pharmaceuticals-nasdaqregn-to-strong-buy-2026-08-15/
Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline?
August 14 at 7:08 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/biohaven-bhvn-latest-regeneron-pharmaceuticals-222352923.html
GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk)
August 14 at 7:08 PM  |  fool.comhttps://www.fool.com/investing/2026/08/14/glp-1-demand-is-soaring-2-stocks-that-could-benefi/
Regeneron Pharmaceuticals, Inc. (REGN) Investors: September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit - Hagens Berman
August 14 at 3:34 PM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/regeneron-pharmaceuticals-inc-regn-investors-september-14-2026-lead-plaintiff-deadline-in-class-action-lawsuit--hagens-berman-302852043.html
BMS builds big in Texas; Regeneron backs would-be rival
August 14 at 2:07 PM  |  pharmavoice.comP
The Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 14, 2026 - REGN
August 14 at 10:33 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/14/3345457/0/en/the-gross-law-firm-reminds-regeneron-pharmaceuticals-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-september-14-2026-regn.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

argenex stock logo

argenex NASDAQ:ARGX

$987.84 +136.55 (+16.04%)
As of 04:00 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Insmed stock logo

Insmed NASDAQ:INSM

$128.32 +4.58 (+3.70%)
As of 04:00 PM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Natera stock logo

Natera NASDAQ:NTRA

$314.18 +4.25 (+1.37%)
As of 04:00 PM Eastern

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Regeneron Pharmaceuticals stock logo

Regeneron Pharmaceuticals NASDAQ:REGN

$805.93 +2.45 (+0.30%)
As of 04:00 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas